Introduction
The retinoids are natural and synthetic derivatives of vitamin A. Vitamin A is required for vision, fertility, immune function, and maintaining cellular and tissue homeostasis. 1, 2 Retinoids are physiologically important during development and regulate diverse cellular growth and differentiation programs. At pharmacological dosages, retinoids are active in the treatment of acute promyelocytic leukemia (APL) as well as other malignancies, certain premalignant and nonmalignant disorders, as reviewed. 3 Retinoids activate transcription by binding two families of nuclear transcription factors: retinoic acid receptors (RARs) and retinoid X receptors (RXRs). 4, 5 Each of these families contains three members (a, b, and g) and can express multiple isoforms. Unliganded retinoid receptors bind specific retinoic acid response elements (RARE) in the genome and recruit nuclear corepressors such as a nuclear receptor corepressor (N-CoR) and a silencing mediator of RAR and thyroid hormone receptor (SMRT). 6, 7 Nucleosome assembly and transcriptional repression are regulated by histone deacetylases as well as by methylationinduced silencing, as reviewed. 8, 9 Retinoid binding to these receptors leads to release of corepressors and recruitment of transcriptional coactivators. 10 Transcription of retinoid target genes triggers specific biological effects.
Cell and tissue specificity in retinoid biology can be conferred by the pharmacological properties of a retinoid receptor agonist or antagonist and the pattern of expressed retinoid nuclear receptors. The expression of specific retinoid receptors is cellcontext dependent and mediates specific retinoid functions in cells and tissues. 11 For example, all-trans-retinoic acid (RA)-induced differentiation of the embryonal carcinoma NT2/ D1 cell line depends on RARg, 12 while in APL retinoid response is linked to PML/RARa expression. 3 While both these models undergo terminal differentiation and growth suppression after RA treatment, they engage different retinoid receptors to signal these effects. In addition to tissue specificity in retinoid signaling, signals are generated by different retinoids based on receptor binding affinities. For example, RA activates RARs, and 9-cis-retinoic acid is bifunctional, activating the RAR and RXR pathways. 13, 14 To activate specific retinoid nuclear receptor pathways, synthetic agonists or antagonists have been engineered. 15, 16 Retinoid signaling can also occur through mechanisms independent of retinoid receptors. N-(4-hydroxyphenyl) retinamide and some other synthetic retinoids can act through retinoid receptor-independent mechanisms to induce apoptosis preferentially. [17] [18] [19] [20] Corepressor and coactivator interactions as well as epigenetic modifications such as DNA methylation likely contribute to cell-and tissue-specific responses to retinoid treatment.
RA treatment induces APL cell differentiation in the clinic. [21] [22] [23] These responses depend on the expressed RARa translocation partners. 3 Variant APL translocations rearrange RARa with the promyelocytic leukemia zinc-finger (PLZF), 24 nucleophosmin (NPM), 25 signal transducer and activator of transcription (STAT5b), 26 or nuclear mitotic apparatus genes (NUMA). 27 The t(15;17) translocation results in PML/RARa expression and is of clinical interest since it predicts complete remission following RA-based differentiation therapy. 28 In contrast, the variant t(11;17) translocation product, PLZF/RARa, is associated with RA resistance. 29 Clinical RA response is tightly linked to the expression of specific molecular rearrangements in APL.
Clinical remissions that follow RA-based differentiation therapy in APL represent successful examples of targeted therapy. Remission induction is associated with leukemic cell differentiation, especially in PML/RARa-expressing APL cases. This clinical finding provided a rationale to uncover the oncogenic effects of the APL fusion proteins and molecular mechanisms for differentiation therapy. Identification of RA target genes represents a critical step in developing a fuller understanding of the mechanisms responsible for effective differentiation-based therapy in APL. This review focuses on what is now known about retinoid target genes in APL.
APL models
Cellular and transgenic APL models have proven useful for studying mechanisms of retinoid response. The NB4 APL cell line is often used to explore these mechanisms. The NB4 APL cell line was originally derived from an APL case that contained the t(15;17) rearrangement and expressed PML/RARa. RA treatment triggers terminal myeloid differentiation of NB4 cells. 30 RA-resistant NB4 APL cell lines have also been derived by several groups, as reviewed. 3 RA-resistant cells have acquired specific defects including persistent telomerase activity, sustained PML oncogenic domain (POD) disorganization, mutations in the ligand-binding domain of the RARa portion of PML/RARa, or deregulation of RA target genes, among other changes. 3, 30, 31 Other myeloid leukemic cell lines exist that do not express PML/RARa but are retinoid responsive, such as the HL60 or U937 lines. The role of PML/RARa in mediating RA response in these and other cell contexts has been studied through PML/RARa transfection studies. [32] [33] [34] [35] [36] These studies highlighted the inhibitory effects of this translocation product on the PML and RARa pathways as well as on retinoid-induced myeloid differentiation. Studies in the NB4 cell line also uncovered RA-dependent degradation of PML/RARa as a hallmark of retinoid response. 37 Recently, microarray analysis uncovered species implicated in this degradation program, as will be discussed.
Transgenic models exist that express PML/RARa or other APL translocation products. Engineered expression of PML/RARa under the control of myeloid-specific promoters in transgenic models has provided mechanistic insights into the role of this and other fusion products in APL. [38] [39] [40] [41] [42] Phenotypes associated with these transgenic lines resulted in abnormal myelopoiesis or myeloid leukemia that was of an APL or non-APL histopathology, as determined by the promoter context used. Leukemia typically developed with low penetrance in these transgenic lines and with a long latency, indicating that additional genetic events promoted leukemogenesis. A transgenic line expressing both the PML/RARa and RARa/PML fusion products was engineered and had increased incidence of leukemia as compared to prior models expressing only PML/RARa. 43 While results obtained using transgenic lines directly implicated PML/ RARa in abnormal myeloplasia and leukemogenesis, the low incidence and long latency for development of leukemia led to a second hit hypothesis.
This hypothesis was recently validated in a transgenic model. Coexpression of PML/RARa and FLT3-ITD -a constitutively active tyrosine kinase that is often expressed in APL -led to the rapid development of promyelocytic leukemia in these transgenic lines. 42 Involvement of FLT3-ITD in leukemogenesis has provided interest in the development of FLT3-ITD inhibitors. Recently developed FLT3-ITD inhibitors have promise in the treatment of APL. 44, 45 Identification of other genetic alterations in addition to the expression of specific translocation products is important to understand the pathogenesis of APL better. These genetic alterations could represent novel therapeutic targets. PML/RARa expression predicts RA response in these models. This finding is consistent with the view that PML/RARaexpressing transgenic lines mimic key features of clinical APL RA response. These models should prove useful in investigating the functions of retinoid target genes. As candidate retinoid target genes are highlighted in in vitro cellular models, in vivo APL models could be used to validate their roles in RA response.
PML/RARa acts as a dominant-negative inhibitor of PML-and RARa-dependent pathways. The expression of PML/RARa disorganizes PODs [46] [47] [48] and interferes with the ability of PML to regulate proliferation and apoptosis. PML has been implicated in cell death since PMLÀ/À mice exhibit decreased caspase-1 and caspase-3 activation. 49 Inactivation of PML has been associated with abnormal cell growth and differentiation as well as loss of RA response. 50 Forced PML expression triggers cell death. 51 Transgenic expression of PML/RARa in myeloid cells decreased TNF-, Fas-, and interferon-induced cell death and caspase-3 activation. 49 These findings indicate the inhibitory effects of PML/RARa on cell death or differentiation pathways and highlight the need to identify retinoid target genes that oppose these inhibitory effects of PML/RARa. PML/RARa inhibits RARa signaling. In the absence of a ligand, PML/RARa can homodimerize 52, 53 or heterodimerize with RXR, 53 bind RAREs, 34, 54 and associate with nuclear corepressors. 8, 55 The PML/RARa homodimer exhibits altered DNAbinding specificity. 53, 56 Transcriptional silencing by PML/RARa occurs through changes in histone deacetylase activity 57, 58 or methylation. 59 PML/RARa competes with RARs for RAREs and further inhibits retinoid transcriptional signaling. The interaction between PML/RARa and its corepressors is stable but can be overcome by pharmacological RA dosages. 57, 58 Pharmacological RA dosages can restore signaling pathways and trigger leukemic cell differentiation. Notably, RA treatment also causes degradation of the PML/RARa protein 37, 60, 61 and reorganization of PODs. 46, 47 Target genes responsible for these retinoid effects have only begun to be explored. Conceivably, different target genes are activated by RA treatment to signal each of these effects.
In contrast to PML/RARa transgenic lines, PLZF/RARa transgenic lines are resistant to RA therapy. 62 This resistance mimics clinical findings in variant APL cases. 29 This RA resistance is likely due to differences between distinct fusion proteins. Unlike PML/RARa, PLZF/RARa forms a stable association with the corepressor complex, despite RA treatment. 57, 58, 63 The stability of this complex appears to account for RA resistance in APL cases that express PLZF/RARa. Clinical resistance might be overcome by combination therapy with RA and a histone deacetylase inhibitor. 64 There are aspects of APL biology that are not fully represented in the available models. For example, mutations in addition to the expression of PML/RARa or other fusion products occur in APL pathogenesis. These mutations likely contribute to the clinical sensitivity or resistance of APL cases to retinoids or other therapeutic agents. Experimental models for APL should investigate the functional significance of these mutations and assess therapeutic responses. Models that closely mimic the clinical biology of APL should prove useful in monitoring RA target gene expression and in assessing gene function. It would also be informative to examine target gene expression in hematopoietic cells harvested during RA treatment of clinical APL cases.
An individual transgenic APL model is not likely to reproduce the complexity or heterogeneity evident in clinical APL cases. However, APL models should be useful in identifying mechanisms involved in retinoid resistance or resistance to other therapeutic agents. Comparing patterns of target gene activation in these models could determine the relationship between altered target gene expression and onset of retinoid resistance. Once altered expression of retinoid target genes is linked to retinoid resistance in an APL model, then the finding should be extended to the setting of clinical APL cases that are retinoid SPOTLIGHT resistant. Through examination of defined APL-transgenic models and selected APL cases, the roles of candidate RA target genes in the biology of APL would be uncovered.
Retinoid target genes
RA-induced differentiation in APL involves the regulation of target gene transcription, as summarized in Figure 1a . Different target genes likely induce distinct biological effects. Linking target gene expression to specific functions is important in understanding the precise mechanisms of retinoid action. To date, identification of candidate target genes in APL has resulted from examining changes in gene expression following RA treatment. These changes in gene expression have become evident from large-scale screens that are now readily available. Several methods exist to assess global changes in gene expression such as microarray analysis, differential display RT-PCR, subtractive-selective hybridization, among other approaches.
- 
SPOTLIGHT
A frequent concern raised as part of expression screening studies such as microarray analysis is that changes in gene expression might not confer changes in function. A marked change in gene transcription following RA treatment could occur without triggering a major biological effect. Alternatively, a modest change in gene expression could be of major functional significance. In choosing candidate targets for in-depth study, investigators often focus on those targets that exhibit marked alterations in expression. It is hypothesized that these changes could represent biological signals. Another reason for studying these changes is that a dramatic change in gene expression would not likely be artifactual. Major changes in gene expression are readily detected. However, it is prudent not to attribute functional importance to this in the absence of confirmatory biochemical data.
Comprehensive screens that identify changes in gene expression during RA-induced differentiation in APL offer an insight into retinoid effects on transcription. These can highlight potential RA target genes in APL. One approach has used an Affymetrix-based strategy to detect changes in gene expression profiles in APL and other leukemic cell differentiation programs. 65 RA treatment of NB4 APL cell differentiation was studied as well as maturation programs activated in other leukemic cell lines following treatment with other differentiation agents. Gene expression profiles were examined before and after these treatments. Self-organizing maps were used to identify species that were directly responsible for RA response in APL. This approach identified 154 species as preferentially induced by RA treatment in NB4 cells. Although markers of neutrophilic differentiation and previously implicated RA target genes were among the highlighted species, several novel candidate RA targets were also identified. A limitation of microarray experiments is that findings obtained depend on the complexity of the species displayed on an individual DNA array. For this reason, other assays have been developed.
In the search for retinoid target genes, other screening strategies have been used including suppression-subtractive hybridization, differential-display RT-PCR, and cDNA array-based technologies. 66 These technologies have identified 169 retinoid regulated species in APL, including 100 that were induced and 69 that were repressed. Cycloheximide treatment did not affect regulation of 32 of these speciesimplicating these species as direct retinoid targets. Many of the upregulated species were induced within 12-48 h of RA treatment. Of the repressed species, 59 were affected within 12 h of RA treatment. Whether these species were deregulated in RA-resistant APL cells was not examined. Although these screens used different technical approaches as compared to prior work, 65 considerable overlap was found in the highlighted species. 66 Identification of potential RA target genes through the use of several independent screens offers a sound approach for determining retinoid-regulated species and associated pathways. As additional screens are completed 67 to search for RA target genes in APL, novel target genes would be uncovered and previously implicated species would be highlighted. This should reveal the network of signals involved in RA response in APL.
Different cassettes of retinoid regulated species could account for diverse effects on cellular growth and differentiation induced by RA treatment of APL cells. 65, 66 Species involved in transcriptional regulation, regulation of apoptosis, cell-cycle regulation, proliferation, and protein modifications were among retinoid-induced species. Of the species that were repressed were those known to be involved in DNA synthesis or repair, cyclins, MAPK pathway, and transcription factors associated with cellular proliferation, among other pathways. Each cassette of regulated gene products might affect specific aspects of RA response. Evaluating this possibility requires an in-depth study of each gene product. It is a laborious process to validate a specific target gene. It is important that a candidate target gene is not only RA regulated but also plays a functional role in mediating RA response in APL.
Candidate RA target genes in APL should be functionally validated. Since many potential target genes exist, it is worthwhile to establish features that distinguish direct regulators of RA response. These species typically exhibit: (1) rapid RA regulation that precedes morphologic maturation or other key biological effects, (2) deregulation in RA-resistant cells, (3) retinoid-responsive motifs in their promoters, (4) signaling of retinoid biological effects once introduced into responsive cells, and (5) reversal of retinoid resistance when introduced into cells that have become resistant due to aberrant expression of an individual target gene. Specific RA-regulated species have been highlighted as candidate RA target genes in APL, as depicted in Figure 1b . These have been linked to the triggering of differentiation, apoptosis, or degradation of PML/RARa. There exist databases that contain other putative RA target genes in APL. This is especially the case for those data sets that are publicly available. 65, 68 The CCAAT/enhancer-binding protein e (C/EBPe) is a member of the C/EBP nuclear transcription factor family that was expressed predominantly in myeloid cells. The C/EBPe promoter was reported to contain RAREs and this species is activated during RA-induced granulocytic differentiation of NB4 APL cells. 69, 70 Retinoid regulation of C/EBPe was linked preferentially to granulocytic differentiation since RA priming followed by phorbol ester (PMA) or vitamin D 3 treatmentsthat induce NB4 cells to differentiate along the monocytic pathway -repressed rather than induced C/EBPe. 71 A functional association between C/EBPe expression and granulocytic differentiation was established by demonstrating that engineered C/ EBPe expression in U937 leukemic cells triggered granulocytic differentiation even in the absence of RA treatment. 69 When introduced into leukemic cells from PML/RARa transgenic mice, the expression of C/EBPe enhanced survival. 70 These findings implicated C/EBPe as playing a key role in the induction of APL differentiation. This also indicated the important role of target gene expression in the biology of APL.
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) was identified as a putative RA target gene in APL. Its features are distinct from the other RA target genes. 72 Although RA treatment of NB4 APL cells is often associated with induction of granulocytic differentiation, prolonged exposure of NB4 APL cells to RA leads to postmaturation apoptosis. Findings revealed that RA treatment of NB4 APL cells caused the early regulation of multiple, perhaps antagonistic prosurvival or prodeath programs. Chronic RA treatment signaled cell death through induction of the cell death ligand, TRAIL. This species was deregulated in RA-resistant APL cells. 72 Exposure of retinoidsensitive or -resistant APL cells to TRAIL caused cell death even in the absence of RA treatment, and neutralization of TRAIL blocked RA-induced cell death. 72 The TRAIL ligand is a distinct RA target gene in APL as it has not yet been associated with RA-induced differentiation. The ability of TRAIL to cause cell death in both RA-sensitive and -resistant APL cells highlighted this species as a pharmacological target in APL and perhaps other malignancies. 72, 73 The ubiquitin-activating enzyme E1-like protein (UBE1L) was identified as a potential lung tumor suppressor gene. 74 It maps to chromosome 3p21, a region frequently deleted in lung
Retinoid target genes in APL I Pitha-Rowe et al cancers. 75 Microarray analysis identified UBE1L as an RA-regulated species in APL. 65 While UBE1L was not found to be the most prominent RA-induced species in NB4 cells, it was highlighted as a candidate target gene through bioinformatic analysis and the recognition that RA can activate a proteasomedependent degradation program. This retinoid degradation program was shown to be an important step in induced tumor cell differentiation 76 and in RA-mediated chemoprevention.
77
UBE1L was implicated directly as an RA target gene in APL since UBE1L mRNA and protein were induced by RA treatment in retinoid-sensitive but not-resistant NB4 cells. 78 The effects of UBE1L in APL cells is summarized in Figure 1b . The UBE1L promoter can mediate a transcriptional response to RA treatment that was enhanced by cotransfection of retinoid receptors. As expected, transcriptional repression occurred after PML/RARa transfection.
78 UBE1L expression was inversely related to PML/ RARa expression, suggesting that UBE1L affects the stability of PML/RARa. This was confirmed through UBE1L transfection experiments that triggered PML/RARa degradation in the absence of RA treatment. 78 Transfection of a truncated UBE1L did not lead to PML/RARa degradation. Notably, retroviral transduction of UBE1L caused apoptosis of NB4 cells. 78 The ability of UBE1L to mimic an important RA effect (degradation of PML/RARa) in APL without RA treatment indicated a functional role for UBE1L in conferring RA response in APL and perhaps other cellular contexts. UBE1L-dependent degradation of PML/ RARa is a novel mechanism linked to RA response. The role of UBE1L in mediating RA response should next be examined in transgenic APL models and in clinical APL cases.
The finding that UBE1L was the E1 enzyme for the interferonstimulated gene 15 kDa (ISG15) offered an insight into the mechanisms of UBE1L action. 79 ISG15 is a ubiquitin-like protein that is rapidly and prominently induced following interferon treatment or microbial challenge. [80] [81] [82] Similar to ubiquitin, ISG15 can become conjugated to target proteins through the formation of an isopeptide bond. 83 Ubiquitin conjugation requires the actions of several enzymes. 84 Ubiquitin is activated through an E1 enzyme in an ATP-dependent manner. This results in the formation of a thiolester bond between the carboxylterminal glycine of ubiquitin and a catalytic cysteine residue within the E1 enzyme. This reaction occurs early in the conjugation process and is necessary for conjugate formation. UBE1L has been reported to act as an E1 enzyme for ISG15. 79 More needs to be learned about the identity of ISG15 biochemical targets and their biological roles. Serpin 2A, 85 Stat1, Cg1, Jak1, and ERK1 86 were recently identified as ISG15 conjugates. An ISG15 deconjugating enzyme, ubiquitin-specific protease 43 kDa (UBP43, USP18), has been studied. Work on the UBP43 knockout mouse and other model systems revealed that regulation of UBP43 and ISG15 conjugates regulated cellular differentiation 87 and response to type I interferons. 88 Interestingly, the chromosomal location of UBP43 (22q11.2) is frequently deleted in DiGeorge syndrome and velocardiofacial syndrome. 89 The biological importance of this conjugation needs to be determined. Identifying UBE1L as involved in the ISG15 conjugation pathway provides a potential insight into the role of ISG15 conjugation in RA-mediated differentiation of APL. Current work focuses on understanding the precise roles played by UBE1L and ISG15 in APL differentiation. Studies of UBE1L indicate how investigation of a single target gene can uncover a network of pathways involved in RA-induced APL differentiation.
C/EBPe, UBE1L, and TRAIL fulfill key features of an RA target gene. Their expression is regulated by RA treatment in retinoidsensitive but not -resistant APL cells. Transactivation studies of C/EBPe and UBE1L revealed that the promoters of these respective genes were activated by RA treatment and cotransfection of retinoid receptors, while transcriptional repression followed PML/RARa co-transfection. C/EBPe has been shown to be a direct target of retinoid receptors. It is important to recognize that an RA target gene might act indirectly through the actions of retinoid-regulated auxiliary proteins. Establishing the functional relevance of RA target genes in APL requires confirmatory experiments. The first approach is to engineer overexpression of the candidate target gene in APL lines and then assay for RA-induced effects in the absence of RA treatment. Engineered expression of an RA target gene in retinoid-resistant APL cells might overcome this resistance. In this regard, forced expression of C/EBPe in leukemic cells lacking PML/RARa was sufficient to induce granulocytic differentiation. Notably, exposure of RA-sensitive or -resistant NB4 cells to TRAIL caused cell death. UBE1L transfection also mimicked a key feature of the RA response in APL, PML/RARa degradation, as summarized in Figure 1b . Retroviral transduction of UBE1L into NB4 cells led to apoptosis. This result was not unexpected. Ribozyme-mediated degradation of PML/ RARa 90, 91 or arsenic-mediated 92 degradation of PML/RARa also triggered apoptosis of APL cells. RA treatment triggered PML/ RARa degradation as well as leukemic cell differentiation. This implicated the involvement of target genes other than UBE1L that would induce maturation in APL.
Other candidate RA target genes exist in APL, but these need to be functionally validated. One example is GOS2 that was markedly induced by RA treatment in NB4 APL cells. 65 Another is B94, a tumor necrosis factor alpha (TNFa)-inducible species that was increased rapidly after RA treatment of NB4 cells and APL blasts as well as during myelopoiesis. 93, 94 The functional role of B94 and GOS2 in APL needs to be discerned.
The clinical activity of retinoids in non-APL settings provided an impetus for discovery of retinoid target genes in other models. Results from these investigations revealed that while there was an overlap in the identity of some RA target genes between experimental models, each model had unique transcriptional responses to RA treatment. For example, the NT2/D1 cell is a multipotent human embryonal carcinoma cell line that can differentiate into a neuronal phenotype and other lineages after RA treatment. 95 Gene expression profiling has been used to identify RA targets in human embryonal carcinoma cells. 96 This identified several RA-regulated species that might function as RA target genes. For instance, receptor interacting protein 140 (RIP140) is a nuclear receptor coregulator that was an early and rapidly induced species in NT2/D1 cells. Retinoid induction of RIP140 could provide a negative feedback on gene expression mediated by ligand-activated retinoid receptors. 97 The use of retinoids in cancer chemoprevention led to the development of a human bronchial epithelial chemoprevention model. 98 Immortalized human bronchial epithelial cells were malignantly transformed after independent exposure to the tobacco-derived carcinogens: N-nitrosamine-4-(methylnitrosamino)-1-(3pyridyl)-1-butanone (NNK) or cigarette smoke condensate (CSC). 98 RA treatment prevented NNK-or CSC-dependent carcinogenic transformation of these cells. 98 Analysis of retinoid chemoprevented vs carcinogen-transformed human bronchial epithelial cells should uncover retinoid targets that are important in chemoprevention. An examination of acute effects of RA treatment in human bronchial cells determined that certain candidate RA target genes were regulated as in other models, but some retinoid-regulated species were specifically regulated by RA treatment of these cells. 99 Retinoid actions are cell-and tissue-context specific. Actions of retinoids in APL and other settings regulate species that affect SPOTLIGHT proliferation, differentiation, apoptosis, and other processes. Retinoids in different cellular and tissue contexts engage specific retinoid receptors and initiate distinct cellular and differentiation programs. While similar RA target genes appear to be activated by RA treatment of different models, there are already examples of distinct target genes as regulated in individual differentiation models. Gene expression profiling should uncover the cassettes of species that confer these specific biological effects. As proteomic techniques mature, 100 retinoid target genes uncovered through genomic approaches should be validated at the level of protein expression. Ultimately, the functional role of RA target genes should be assessed in the clinic. A further understanding of the role of these target genes should provide insights into the mechanisms of retinoid response or resistance in APL and other malignancies. Emerging technologies in functional genomics such as the use of small interfering RNA (siRNA) 101 will facilitate a functional understanding of specific retinoid target genes in APL.
Conclusions
Identification of RA target genes is an important step towards a mechanistic understanding of RA response in APL. A characteristic of RA target genes is that their forced expression in APL cells can signal key features of retinoid response even in the absence of RA treatment. To date, several putative target genes have been identified in APL. Examples include C/EBPe that can induce maturation of APL cells, TRAIL that can induce postmaturation apoptosis in RA-sensitive or -resistant APL cells, and UBE1L that can trigger PML/RARa degradation and signal apoptosis of APL cells that express PML/RARa. Interactions between these RA targets may occur in APL and other cell contexts. Future work should uncover additional RA target genes in APL and other tumor cell contexts. Whether these highlighted species represent novel pharmacologic targets should be determined. Available cellular models such as RA-sensitive or -resistant NB4 APL lines as well as transgenic APL models are useful resources for mechanistic studies of these target genes. Genomic and proteomic techniques will likely reveal the network of signals that account for diverse biological effects of RA. Understanding these signals could lead to advances in the retinoid treatment of APL and other malignancies.
